Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
Key PointsAnalysts also raised their price targets on the company...
Nasdaq News: Markets
More News
Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today?
Strong results, clinical progress, capital raises and bullish analyst calls boosted investor confidence.
Stocktwits
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to...
Business Wire
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.
Zacks
Dow, S&P 500, Nasdaq Futures Slip As Global Bond Rout Catches Up With Markets: LUNR, MSTR, WYFI, AMLX Stocks In Focus
The U.S. 30-year Treasury yield climbed to a fresh 19-year high on Tuesday, trading at 5.274% at the time of writing, while the 10-year Treasury yield was at 4.692%.
Stocktwits
Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today?
Investors responded to clinical progress, improving commercial performance and new growth opportunities.
Stocktwits
Profusa, Baidu, Amylyx Pharmaceuticals, FreeCast and Klarna Group: Why These 5 Stocks Are on Investors' Radars Today
PFSA, BIDU, AMLX, CAST, KLAR were among the stocks seen trending on Tuesday, Aug. 18, 2026.read more...
Key PointsAmylyx is developing a GLP-1 treatment for people with chronic low blood sugar...
Nasdaq News: Markets
AMLX Stock Clocks Best Day Ever After Positive Trial Data, Launches $350M Offering
The capital raise comes as Amylyx prepares to move from clinical success toward potential commercialization, following the positive trial data for avexitide announced earlier today.
Stocktwits
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. In addition, Amylyx intends to grant the underwriters a 30-day option to purchase up to an additional $52.5...